New updates have been reported about Adcendo.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adcendo has raised an oversubscribed $75 million Series C round to extend its cash runway through multiple clinical inflection points for its antibody-drug conjugate pipeline targeting high unmet-need cancers. The financing, led by Jeito Capital with new backing from Vida Ventures, BPI France, and Denmark’s EIFO alongside all existing investors, is intended to fund three first- and best-in-class ADC programs through near-term data readouts.
Capital will support expansion of the ADCE-T02 Tissue Factor ADC in the Phase I Tiffany-01 trial across several hard-to-treat solid tumors, continued dose escalation and expansion of ADCE-D01 (uPARAP) in soft tissue sarcoma and other mesenchymal cancers, and advancement of ADCE-B05, an undisclosed-target ADC in squamous cell carcinomas. As part of the transaction, Jeito’s Ksenija Pavletic and Vida Ventures’ Rajul Jain will join Adcendo’s board, strengthening investor oversight as the Copenhagen- and Boston-based company pushes toward value-defining clinical milestones that could materially shape its partnering options, future fundraising needs, and strategic direction.